Clinical Validation of the MammaTyper LRP Model for Identification of Low-Risk Patients With Early-Stage ER+/HER2- Breast Cancer: From Subtyping to Chemotherapy De-escalation.

Ding M, Zhang H, Wu Q, Xiang H, Cheng Y, Xu L

Open source

DOI
10.1016/j.clbc.2026.08.015
Published
2026 Aug 24
Container
Clinical breast cancer
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.clbc.2026.08.015,
  title = {Clinical Validation of the MammaTyper LRP Model for Identification of Low-Risk Patients With Early-Stage ER+/HER2- Breast Cancer: From Subtyping to Chemotherapy De-escalation.},
  author = {Ding M and Zhang H and Wu Q and Xiang H and Cheng Y and Xu L},
  year = {2026},
  journal = {Clinical breast cancer},
  doi = {10.1016/j.clbc.2026.08.015},
  url = {https://doi.org/10.1016/j.clbc.2026.08.015}
}

RIS

TY  - JOUR
TI  - Clinical Validation of the MammaTyper LRP Model for Identification of Low-Risk Patients With Early-Stage ER+/HER2- Breast Cancer: From Subtyping to Chemotherapy De-escalation.
AU  - Ding M
AU  - Zhang H
AU  - Wu Q
AU  - Xiang H
AU  - Cheng Y
AU  - Xu L
PY  - 2026
JO  - Clinical breast cancer
DO  - 10.1016/j.clbc.2026.08.015
UR  - https://doi.org/10.1016/j.clbc.2026.08.015
ER  - 

APA

M, D., H, Z., Q, W., H, X., Y, C., & L, X. (2026). Clinical Validation of the MammaTyper LRP Model for Identification of Low-Risk Patients With Early-Stage ER+/HER2- Breast Cancer: From Subtyping to Chemotherapy De-escalation.. Clinical breast cancer. https://doi.org/10.1016/j.clbc.2026.08.015

Source records